Cargando…

What can we learn from molecular dynamics simulations for GPCR drug design?

Recent years have seen a tremendous progress in the elucidation of experimental structural information for G-protein coupled receptors (GPCRs). Although for the vast majority of pharmaceutically relevant GPCRs structural information is still accessible only by homology models the steadily increasing...

Descripción completa

Detalles Bibliográficos
Autores principales: Tautermann, Christofer S., Seeliger, Daniel, Kriegl, Jan M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Research Network of Computational and Structural Biotechnology 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4334948/
https://www.ncbi.nlm.nih.gov/pubmed/25709761
http://dx.doi.org/10.1016/j.csbj.2014.12.002
_version_ 1782358257931649024
author Tautermann, Christofer S.
Seeliger, Daniel
Kriegl, Jan M.
author_facet Tautermann, Christofer S.
Seeliger, Daniel
Kriegl, Jan M.
author_sort Tautermann, Christofer S.
collection PubMed
description Recent years have seen a tremendous progress in the elucidation of experimental structural information for G-protein coupled receptors (GPCRs). Although for the vast majority of pharmaceutically relevant GPCRs structural information is still accessible only by homology models the steadily increasing amount of structural information fosters the application of structure-based drug design tools for this important class of drug targets. In this article we focus on the application of molecular dynamics (MD) simulations in GPCR drug discovery programs. Typical application scenarios of MD simulations and their scope and limitations will be described on the basis of two selected case studies, namely the binding of small molecule antagonists to the human CC chemokine receptor 3 (CCR3) and a detailed investigation of the interplay between receptor dynamics and solvation for the binding of small molecules to the human muscarinic acetylcholine receptor 3 (hM3R).
format Online
Article
Text
id pubmed-4334948
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Research Network of Computational and Structural Biotechnology
record_format MEDLINE/PubMed
spelling pubmed-43349482015-02-23 What can we learn from molecular dynamics simulations for GPCR drug design? Tautermann, Christofer S. Seeliger, Daniel Kriegl, Jan M. Comput Struct Biotechnol J Article Recent years have seen a tremendous progress in the elucidation of experimental structural information for G-protein coupled receptors (GPCRs). Although for the vast majority of pharmaceutically relevant GPCRs structural information is still accessible only by homology models the steadily increasing amount of structural information fosters the application of structure-based drug design tools for this important class of drug targets. In this article we focus on the application of molecular dynamics (MD) simulations in GPCR drug discovery programs. Typical application scenarios of MD simulations and their scope and limitations will be described on the basis of two selected case studies, namely the binding of small molecule antagonists to the human CC chemokine receptor 3 (CCR3) and a detailed investigation of the interplay between receptor dynamics and solvation for the binding of small molecules to the human muscarinic acetylcholine receptor 3 (hM3R). Research Network of Computational and Structural Biotechnology 2014-12-10 /pmc/articles/PMC4334948/ /pubmed/25709761 http://dx.doi.org/10.1016/j.csbj.2014.12.002 Text en © 2014 The Authors. Tautermann et al. Published by Elsevier B.V. on behalf of the Research Network of Computational and Structural Biotechnology. http://creativecommons.org/licenses/by/3.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Article
Tautermann, Christofer S.
Seeliger, Daniel
Kriegl, Jan M.
What can we learn from molecular dynamics simulations for GPCR drug design?
title What can we learn from molecular dynamics simulations for GPCR drug design?
title_full What can we learn from molecular dynamics simulations for GPCR drug design?
title_fullStr What can we learn from molecular dynamics simulations for GPCR drug design?
title_full_unstemmed What can we learn from molecular dynamics simulations for GPCR drug design?
title_short What can we learn from molecular dynamics simulations for GPCR drug design?
title_sort what can we learn from molecular dynamics simulations for gpcr drug design?
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4334948/
https://www.ncbi.nlm.nih.gov/pubmed/25709761
http://dx.doi.org/10.1016/j.csbj.2014.12.002
work_keys_str_mv AT tautermannchristofers whatcanwelearnfrommoleculardynamicssimulationsforgpcrdrugdesign
AT seeligerdaniel whatcanwelearnfrommoleculardynamicssimulationsforgpcrdrugdesign
AT kriegljanm whatcanwelearnfrommoleculardynamicssimulationsforgpcrdrugdesign